# Piramal Pharma: how the business works

> For learning only. Cityfort is not a SEBI-registered adviser and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

Piramal Pharma Limited · NSE: PPLPHARMA · BSE: 543635 · Sector: Healthcare

Updated for Q2 FY27 · checked 12 Nov 2026

This is the plain-text version of https://cityfort.in/stocks/piramal-pharma. Source ids in [brackets] refer to the list at the end. Credit: "Cityfort, Piramal Pharma: how the business works", with the page URL.

## In short

Drug companies, hospitals and Indian shoppers pay Piramal Pharma; of every ₹100 that came in during FY26, ₹35.4 went on materials and ₹26.4 on staff, and costs ended ₹3.6 above income.

- By the company's presentation figures, contract development and manufacturing (CDMO) brought in 55% of FY26 revenue, hospital generics 30% and consumer brands 14%.
- FY26 ended in a ₹326 crore loss after ₹196 crore of one-off charges; in Q2 FY27 revenue rose 28.1% from a year earlier and profit for owners was ₹5.6 crore.

## Key facts

**What does Piramal Pharma do?**

Piramal Pharma, based in Mumbai, develops and makes medicines under contract for other drug companies, sells anaesthesia and other hospital medicines in more than 100 countries, and sells consumer health brands in India. Piramal Pharma's FY26 revenue was ₹8,869 crore. [S1, S8, S39]

**How does Piramal Pharma make money?**

Piramal Pharma earns most from contract development and manufacturing (CDMO), which was 55% of FY26 revenue by the company's presentation figures; complex hospital generics were 30% and consumer healthcare 14%. Piramal Pharma's audited accounts report a single pharmaceuticals segment. [S20, S6]

**Who are Piramal Pharma's customers?**

Piramal Pharma's customers include more than 500 drug companies for contract work, over 6,000 hospital customers for its hospital medicines, and over 180,000 chemist and cosmetics outlets in India for its consumer brands. Piramal Pharma's largest contract-manufacturing customer was 6% of FY26 CDMO revenue. [S1, S39, S20]

**How big is Piramal Pharma?**

Piramal Pharma had FY26 revenue of ₹8,869 crore and a loss of ₹326 crore, against revenue of ₹9,151 crore and a profit of ₹91 crore in FY25. Piramal Pharma had 6,617 permanent employees and 17 development and manufacturing sites in FY26. [S8, S12, S42, S1]

**Who owns Piramal Pharma?**

In Sep 2026 Piramal Pharma's promoter group (the Ajay Piramal family, its trusts and group companies) held 34.80%, with no shares pledged. CA Alchemy Investments, a Carlyle affiliate, held 17.93% of Piramal Pharma, other foreign investors 13.65%, Indian institutions 14.44% and the public and others 19.18%. [S27, S39]

**When did Piramal Pharma list?**

Piramal Pharma took over Piramal Enterprises' pharma business under a demerger scheme effective 18 Aug 2022, with 1 Apr 2022 as the appointed date, and Piramal Pharma's shares listed on NSE and BSE on 19 Oct 2022. Its FY23 annual report says FY23 may not be comparable with FY22. [S4]

**How much debt does Piramal Pharma have?**

On 30 Sep 2026 Piramal Pharma had borrowings of ₹5,665 crore and cash and current investments of ₹830 crore, so net debt was ₹4,835 crore (Cityfort calculation). CARE rated Piramal Pharma AA with a stable outlook on 17 Jul 2026. [S6, S39]

**Does Piramal Pharma pay a dividend?**

Piramal Pharma paid ₹0.11 a share for FY24 and ₹0.14 a share for FY25, and proposed no dividend for FY26, a year in which Piramal Pharma made a loss of ₹326 crore. [S3, S2, S1]

## What does Piramal Pharma sell?

Piramal Pharma has three businesses. It develops and makes medicines for other drug companies, sells specialised hospital medicines such as anaesthesia gases, and sells over-the-counter health brands in India.

- **Contract development and manufacturing (CDMO, Piramal Pharma Solutions):** Drug companies hire it to develop a medicine's recipe and then make the active ingredient or the finished dose. 157 molecules were in development for customers in Mar 2026. The company's figure for FY26 revenue was ₹4,915 crore, down 10%. [S1, S39, S20]
- **Complex hospital generics (Piramal Critical Care):** Inhaled anaesthesia such as sevoflurane, spinal (intrathecal) pain and spasticity medicines, and injectable anaesthesia, sold to hospitals. The company's figure for FY26 revenue was ₹2,703 crore, up 3%. [S20, S39]
- **Kenalog brands:** A corticosteroid injection (triamcinolone acetonide) for inflammation, sold in 15 countries under names such as Kenalog, Kenacort and Adcortyl. Bought from Bristol-Myers Squibb for US$35 million upfront plus up to US$65 million on milestones; completed on 1 Apr 2026, with first sales in Q2 FY27. [S56, S57, S18]
- **Consumer healthcare (Piramal Consumer Healthcare):** About 25 over-the-counter brands sold through chemists, shops and online in India. The company's figure for FY26 revenue was ₹1,274 crore, up 17%. [S20, S39]

## Who pays Piramal Pharma?

- **Drug companies (CDMO) (55.0% of revenue):** Big pharma (32% of FY26 CDMO revenue), emerging biotech companies (33%), generics makers (27%) and others; more than 500 customers. Share is the company's presentation figure. [S20, S1]
- **Hospitals and their buyers (hospital generics) (30.0% of revenue):** More than 6,000 hospital customers in over 100 countries; inhalation anaesthesia was 64% of FY26 hospital generics revenue. Share is the company's presentation figure. [S20, S39]
- **Indian consumers (consumer healthcare) (14.0% of revenue):** Sold through more than 180,000 chemist and cosmetics outlets, 13,000 modern-trade stores and online; e-commerce was 27% of FY26 consumer sales. Share is the company's presentation figure. [S20, S39]
- **Customer concentration:** The company does not name customers. Its largest CDMO customer was 6% of FY26 CDMO revenue and the top 10 were 36% (CARE); with CDMO at 55% of revenue, the largest customer was about 3% of company revenue (Cityfort calculation). [S20, S39]

## Where the money went (FY26)

1. In FY26 Piramal Pharma took in ₹8,869 crore of revenue, ₹213 crore of other income and ₹57 crore as its share of associates' profit.
2. Materials and goods bought took ₹3,239 crore, and employees ₹2,416 crore.
3. Other running costs took ₹2,293 crore.
4. Depreciation took ₹831 crore, interest ₹341 crore, one-off charges ₹196 crore and tax ₹150 crore.
5. Costs were ₹326 crore more than the money that came in, so FY26 ended in a loss.

Sources: S8, S1, S20.

## Key numbers by year (₹ crore)

Financials: consolidated, ₹ crore. Financial year runs April to March (March year end). — = not shown on the page.

| Year | Revenue | EBITDA | EBITDA margin | Net profit | Net margin | EPS (₹ per share) | Operating cash flow | Capital spending | Free cash flow | Sources |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| FY23 | 7,082 | 621 | 8.8% | −186 | −2.6% | −1.57 | 484 | 965 | −481 | S17, S3 |
| FY24 | 8,171 | 1,133 | 13.9% | 17.8 | 0.2% | 0.14 | 1,005 | 712 | 293 | S16, S3, S2 |
| FY25 | 9,151 | 1,445 | 15.8% | 91.1 | 1.0% | 0.69 | 892 | 664 | 228 | S12, S1 |
| FY26 | 8,869 | 725 | 8.2% | −326 | −3.7% | −2.46 | 1,653 | 890 | 763 | S8, S1 |

- EBITDA = profit before interest, tax and wear-and-tear of assets.
- Net profit is the share belonging to the company's owners.

## Balance sheet (as of 30 Sep 2026, ₹ crore)

On 30 Sep 2026 Piramal Pharma's borrowings exceeded its cash and current investments by ₹4,835 crore, about 2.9 times FY26 cash from operations of ₹1,653 crore (Cityfort calculation). [S6, S1, S18, S20, S22, S39]

| Item | Value |
| --- | --- |
| Total debt | 5,665 |
| Cash and investments | 830 |
| Net debt (debt minus cash) | 4,835 |
| Net worth (shareholders' money) | 8,165 |
| Debt to equity (times) | 0.69 |

- Borrowings = long-term ₹4,454 crore + short-term ₹1,212 crore. Cash and investments = cash, other bank balances and current investments. Lease liabilities (₹179 crore on 31 Mar 2026) are not counted.
- Net debt was ₹4,140 crore on 31 Mar 2026 on the same calculation. The company's own figures are ₹4,859 crore for 30 Sep 2026 and ₹4,164 crore for 31 Mar 2026 (₹4,140 crore in its Apr 2026 presentation).
- The company reported net debt of 3.4 times its EBITDA (its definition, which includes other income) on 30 Sep 2026, against 3.7 in March. Asked on 28 Oct 2026 why net debt rose, management named the Lexington expansion, the Kenalog purchase, the Yapan Bio stake and currency movements.
- CARE (17 Jul 2026) calls liquidity strong: about ₹1,332 crore of unencumbered cash and liquid investments on 31 Mar 2026, and working-capital limits of ₹2,702 crore, less than half used.
- Debt to equity = borrowings ÷ total equity of ₹8,165 crore, which includes Yapan Bio's minority holders from Q2 FY27 (Cityfort calculation).

## Who owns Piramal Pharma? (shareholding, Q2 FY27)

| Holder | % of shares |
| --- | --- |
| Promoters | 34.8% |
| Promoter shares pledged (% of promoter shares) | 0.0% |
| Foreign institutions (FII) | 13.65% |
| Indian institutions (DII) | 14.44% |
| Public | 19.18% |
| CA Alchemy Investments, a Carlyle affiliate, shown on its own in every quarter: the filings list it under foreign direct investment (institutions) to Mar 2026 and under foreign companies (non-institutions) from Jun 2026 | 17.93% |

Sources: S27, S28, S29, S30, S31, S32, S33, S34, S35, S36, S37, S38, S39.

## What could go wrong

### Contract orders can swing

CDMO revenue fell 10% in FY26 to ₹4,915 crore, then rose 36% in Q2 FY27 (company figures). In May 2025 management had said customers' inventory adjustments would weigh on FY26. [S20, S18, S26]

What to watch: CDMO revenue each quarter (₹1,424 crore in Q2 FY27, company figure).

### Debt and the rating's limits

Net debt rose from ₹4,140 crore on 31 Mar 2026 to ₹4,835 crore on 30 Sep 2026 (Cityfort calculation). CARE says it could downgrade if net debt stays above 3.5 times its measure of operating profit (PBILDT) or that margin below 12%, on a sustained basis; its FY26 figure was 4.28 times. [S6, S1, S39, S22]

What to watch: The company's net debt to EBITDA (3.4 times on 30 Sep 2026, company figure).

### US FDA inspection results

Plants that supply the US must pass US FDA inspections. Four inspections from Dec 2025 to Sep 2026 ended with Form 483 observations; Morpeth's 7 observations (Sep 2026) had no disclosed outcome by 12 Nov 2026. [S47, S58, S59, S60]

What to watch: The US FDA's response on Morpeth and any new Form 483.

### Tax paid while overseas sites run below capacity

In Q2 FY27 profit before tax was ₹64 crore but tax was ₹77 crore; in FY26 tax was ₹150 crore on a loss before tax. CARE's Jul 2026 report says capacity at overseas sites is underutilised. [S6, S1, S39]

What to watch: Tax against profit before tax each quarter.

### Bayer arrangement ends

The sales and distribution support arrangement with Bayer Pharmaceuticals, which earns commission, ends on 31 Dec 2026 and will not be renewed. The company says it is under 5% of consolidated revenue and does not expect a material impact on profitability. [S44]

What to watch: Revenue in Q4 FY27 (Jan–Mar 2027).

### Currency

Exports were 72.78% of FY26 turnover (BRSR). Management named currency movements among the reasons net debt rose in H1 FY27. [S42, S22]

What to watch: Net debt and revenue in the Q3 FY27 results.

## What to watch

Next: Q3 FY27 results, Date not announced yet.

- **Q3 FY27 results:** No board-meeting date was announced as of 12 Nov 2026. Last year's Q3 results were approved on 28 Jan 2026.
- **FY27 guidance:** Management said on 28 Oct 2026 it expects about 19–20% revenue growth in FY27; H1 FY27 revenue rose 22.9%.
- **Morpeth and Bayer:** The US FDA's response to Morpeth's 7 observations, and revenue after the Bayer arrangement ends on 31 Dec 2026.

## Sources

- S1: Annual Report FY26. Piramal Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/annual_reports/AR_29557_PPLPHARMA_2025_2026_A_12650980_03072026153531.pdf (published 3 Jul 2026)
- S2: Annual Report FY25. Piramal Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/annual_reports/AR_26676_PPLPHARMA_2024_2025_A_02072025124709.pdf (published 2 Jul 2025)
- S3: Annual Report FY24. Piramal Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/annual_reports/AR_24259_PPLPHARMA_2023_2024_02072024151930.pdf (published 2 Jul 2024)
- S4: Annual Report FY23 (ZIP on NSE). Piramal Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/annual_reports/AR_22207_PPLPHARMA_2022_2023_06072023204348_07062023210001.zip (published 6 Jul 2023)
- S6: Q2 FY27 consolidated results, XBRL (integrated filing). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1747277_27102026091803_WEB.xml (published 27 Oct 2026)
- S7: Q1 FY27 consolidated results, XBRL (integrated filing). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1704575_29072026085620_WEB.xml (published 29 Jul 2026)
- S8: Q4 FY26 and FY26 consolidated results, XBRL (integrated filing). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1660701_28042026094251_WEB.xml (published 28 Apr 2026)
- S9: Q3 FY26 consolidated results, XBRL (integrated filing). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1614519_30012026041428_WEB.xml (published 29 Jan 2026)
- S10: Q2 FY26 consolidated results, XBRL (integrated filing). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1566230_05112025090159_WEB.xml (published 5 Nov 2025)
- S11: Q1 FY26 consolidated results, XBRL (integrated filing). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1495857_28072025095505_WEB.xml (published 28 Jul 2025)
- S12: Q4 FY25 and FY25 consolidated results, XBRL (integrated filing). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1439218_14052025094749_WEB.xml (published 14 May 2025)
- S13: Q3 FY25 consolidated results, XBRL. NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_117925_1363802_28012025090457.xml (published 28 Jan 2025)
- S14: Q2 FY25 consolidated results, XBRL. NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_113141_1286531_23102024082948.xml (published 23 Oct 2024)
- S15: Q1 FY25 consolidated results, XBRL. NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_109536_1203146_26072024010031.xml (published 26 Jul 2024)
- S16: Q4 FY24 and FY24 consolidated audited results, XBRL. NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_105678_1120745_10052024092427.xml (published 10 May 2024)
- S17: Q4 FY23 and FY23 consolidated audited results, XBRL. NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_92615_851845_25052023035236.xml (published 25 May 2023)
- S18: Q2 and H1 FY27 press release and investor presentation (27 Oct 2026). Piramal Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/Priyankamehta_27102026210533_PRandIRIntimation27Oct26sd.pdf (published 27 Oct 2026)
- S20: Q4 and FY26 press release and investor presentation (28 Apr 2026). Piramal Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/Priyankamehta_28042026211903_SEIntimationPressReleaseInvestorPresentation.pdf (published 28 Apr 2026)
- S22: Q2 FY27 earnings call transcript (call 28 Oct 2026). Piramal Pharma Ltd (company website). https://ppl-da-website-new-afd-endpoint-bgd4d0c9egf9g2eq.a01.azurefd.net/media/documents/Q2FY27-Piramal-Pharma-transcript.pdf (published 30 Oct 2026)
- S24: Q4 FY26 earnings call transcript (call 29 Apr 2026). Piramal Pharma Ltd (company website). https://ppl-da-website-new-afd-endpoint-bgd4d0c9egf9g2eq.a01.azurefd.net/media/documents/Q4FY26_Transcript.pdf (published 30 Apr 2026)
- S25: Q3 FY26 earnings call transcript (call 29 Jan 2026). Piramal Pharma Ltd (company website). https://ppl-da-website-new-afd-endpoint-bgd4d0c9egf9g2eq.a01.azurefd.net/media/documents/Q3FY26_Transcript.pdf (published 30 Jan 2026)
- S26: Q4 FY25 earnings call transcript (call 15 May 2025). Piramal Pharma Ltd (company website). https://ppl-da-website-new-afd-endpoint-bgd4d0c9egf9g2eq.a01.azurefd.net/media/documents/Q4FY25_Transcript.pdf (published 16 May 2025)
- S27: Shareholding pattern, quarter ended Sep 2026 (XBRL). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1742857_21102026032628_WEB.xml (published 21 Oct 2026)
- S28: Shareholding pattern, quarter ended Jun 2026 (XBRL). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1697240_20072026060616_WEB.xml (published 20 Jul 2026)
- S29: Shareholding pattern, quarter ended Mar 2026 (XBRL). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1654598_20042026115851_WEB.xml (published 20 Apr 2026)
- S30: Shareholding pattern, quarter ended Dec 2025 (XBRL). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1605746_20012026045511_WEB.xml (published 20 Jan 2026)
- S31: Shareholding pattern, quarter ended Sep 2025 (XBRL). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1551721_17102025032408_WEB.xml (published 17 Oct 2025)
- S32: Shareholding pattern, quarter ended Jun 2025 (XBRL). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1514526_19082025110418_WEB.xml (published 21 Jul 2025)
- S33: Shareholding pattern, quarter ended Mar 2025 (XBRL). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_198690_1420964_21042025023117_WEB.xml (published 21 Apr 2025)
- S34: Shareholding pattern, quarter ended Dec 2024 (XBRL). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_195073_1349012_17012025025839_WEB.xml (published 17 Jan 2025)
- S35: Shareholding pattern, quarter ended Sep 2024 (XBRL). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_192970_1278432_18102024055358_WEB.xml (published 18 Oct 2024)
- S36: Shareholding pattern, quarter ended Jun 2024 (XBRL). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_190316_1194636_19072024041817_WEB.xml (published 19 Jul 2024)
- S37: Shareholding pattern, quarter ended Mar 2024 (XBRL). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_187890_1101499_19042024050025_WEB.xml (published 19 Apr 2024)
- S38: Shareholding pattern, quarter ended Dec 2023 (XBRL). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_185084_1030201_19012024060525_WEB.xml (published 19 Jan 2024)
- S39: CARE Ratings press release: ratings reaffirmed, CARE AA; Stable / CARE A1+ (17 Jul 2026). CARE Ratings Ltd. https://www.careratings.com/upload/CompanyFiles/PR/202607120758_Piramal_Pharma_Limited.pdf (published 17 Jul 2026)
- S40: Intimation: CARE upgrade to CARE AA; Stable (21 Jul 2025). Piramal Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/PIRAMALPHARMA_21072025123913_CreditRating.pdf (published 21 Jul 2025)
- S42: Business Responsibility and Sustainability Report FY26. Piramal Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/BRSR_543635_03072026165645.pdf (published 3 Jul 2026)
- S43: NSE bhavcopy (full), 11 Nov 2026. NSE. https://nsearchives.nseindia.com/products/content/sec_bhavdata_full_11112026.csv (published 11 Nov 2026)
- S44: Expiry and non-renewal of Bayer distribution arrangement (1 Oct 2026). Piramal Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/PIRAMALPHARMA_01102026201104_SERegulation30Intimation.pdf (published 1 Oct 2026)
- S45: Changes in senior management: Critical Care President and COO (30 Sep 2026). Piramal Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/PIRAMALPHARMA_30092026175952_SE_IntimationRetirementandAppointmentofSMP.pdf (published 30 Sep 2026)
- S46: GST order-in-original on input tax credit, FY21-FY23 (29 Sep 2026). Piramal Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/PIRAMALPHARMA_29092026105819_TaxOrderSE_intimation.pdf (published 29 Sep 2026)
- S47: US FDA inspection at Morpeth (UK): Form 483 with 7 observations (14 Sep 2026). Piramal Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/PIRAMALPHARMA_14092026195645_SE_Intimation-FDA_Inspection_Morpeth_.pdf (published 14 Sep 2026)
- S48: Exercise of call option for additional stake in Yapan Bio (10 Aug 2026). Piramal Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/Priyankamehta_10082026180821_SE_Disclosure_Call_option_exercise_-_Yapan.pdf (published 10 Aug 2026)
- S49: Completion of acquisition of additional 40.67% in Yapan Bio (18 Aug 2026). Piramal Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/Priyankamehta_18082026113757_SEDisclosure_CompletionofacquistioninYapan.pdf (published 18 Aug 2026)
- S52: GPCB closure directions for Dahej site (4 Feb 2026). Piramal Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/PIRAMALPHARMA_04022026221523_SE_intimation_Dahej_site.pdf (published 4 Feb 2026)
- S53: GPCB interim environmental damage compensation of Rs 1 crore, Dahej (11 Feb 2026). Piramal Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/pratibhamishra_11022026184225_Reg30Intimation.pdf (published 11 Feb 2026)
- S54: GPCB interim revocation of Dahej closure directions (14 Feb 2026). Piramal Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/PIRAMALPHARMA_14022026130943_SEIntimation-revocationofDahej_closure.pdf (published 14 Feb 2026)
- S55: GPCB permanent revocation of Dahej closure directions (3 Jun 2026). Piramal Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/PIRAMALPHARMA_03062026110500_SEIntimationDahej.pdf (published 3 Jun 2026)
- S56: Agreement to acquire Kenalog brands from Bristol-Myers Squibb (28 Jan 2026). Piramal Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/PIRAMALPHARMA_28012026235517_SE_Disclosure_Keyboard_Intimation_signed.pdf (published 28 Jan 2026)
- S57: Completion of Kenalog acquisition (1 Apr 2026). Piramal Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/PIRAMALPHARMA_01042026162539_Draft_SE_Intimation_-_Keyboard_update.pdf (published 1 Apr 2026)
- S58: US FDA inspection at Lexington (USA): Form 483 with 4 observations (11 Dec 2025). Piramal Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/PIRAMALPHARMA_11122025200647_US_FDA_inspection_Lexington.pdf (published 11 Dec 2025)
- S59: US FDA inspection at Digwal (India): Form 483 with 4 observations (14 Feb 2026). Piramal Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/PIRAMALPHARMA_14022026125728_FDAInspection.pdf (published 14 Feb 2026)
- S60: US FDA inspection at Sellersville (USA): Form 483 with 3 observations (10 May 2026). Piramal Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/pratibhamishra_10052026222602_Sellersville_US_FDA_Inspection___002___005___003_.pdf (published 10 May 2026)
- S61: US FDA EIR (VAI) received for Lexington (13 Apr 2026). Piramal Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/pratibhamishra_13042026102334_US_FDA_inspection_Lexington_closure.pdf (published 13 Apr 2026)
- S62: US FDA EIR received for Digwal (18 May 2026). Piramal Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/PIRAMALPHARMA_18052026114326_US_FDA_inspection_Digwal_closure.pdf (published 18 May 2026)
- S63: US FDA EIR received for Sellersville (9 Jul 2026). Piramal Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/PIRAMALPHARMA_09072026105711_US_FDA_inspection_Sellersville_closure.pdf (published 9 Jul 2026)
- S64: Appointment of Suresh Surana & Associates LLP as statutory auditors (13 Jun 2025). Piramal Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/PIRAMALPHARMA_13062025174856_Reg30.pdf (published 13 Jun 2025)
- S66: Changes in KMP and SMP, incl. company secretary (29 Jan 2026). Piramal Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/PIRAMALPHARMA_29012026000147_KMP.pdf (published 29 Jan 2026)
